Yes, Spiriva is FDA-approved for asthma. Specifically, the Spiriva Respimat inhaler has been approved since 2015 for long-term, once-daily maintenance treatment of asthma in patients 12 years of age and older. Many people associate Spiriva with COPD, which was its original use, but it now plays a well-established role in asthma management as an add-on therapy when other medications aren’t providing enough control.
How Spiriva Works in Asthma
Spiriva contains tiotropium, a type of bronchodilator that works differently from the medications most asthma patients are familiar with. Rather than targeting the beta receptors that drugs like albuterol or salmeterol act on, tiotropium blocks a different set of receptors in the airways called muscarinic receptors. Normally, a chemical messenger called acetylcholine binds to these receptors in the smooth muscle lining your airways, causing them to tighten. Tiotropium prevents that binding, which keeps the airways relaxed and open.
Beyond simple bronchodilation, tiotropium also reduces mucus production in the airways. It has a prolonged effect on the receptors that matter most for keeping airways open, which is why a single daily dose provides 24-hour coverage. This makes it fundamentally different from a rescue inhaler: Spiriva is a maintenance medication you take every day whether or not you feel symptoms.
Where Spiriva Fits in Asthma Treatment
Spiriva is not a first-line asthma treatment. International treatment guidelines place it at step 4 on the asthma treatment ladder, meaning it’s recommended as an add-on option for people already taking a medium-dose inhaled corticosteroid combined with a long-acting beta agonist (the combination inhalers many asthma patients use daily). If that combination isn’t controlling your symptoms well enough, adding Spiriva is one of the next options your doctor may consider, alongside increasing your corticosteroid dose or adding other medications.
This positioning matters because it tells you something important: if your asthma is mild and well-controlled with a basic inhaler regimen, Spiriva probably isn’t necessary. It’s designed for people whose asthma remains poorly controlled despite already being on standard controller medications.
How Well It Works
Clinical trial data shows meaningful improvements in lung function when tiotropium is added to existing asthma treatment. Single doses produced sustained increases of roughly 10% in FEV1, the standard measure of how much air you can forcefully exhale in one second. In head-to-head comparisons, tiotropium actually improved pre-bronchodilator lung function slightly more than salmeterol (a commonly used long-acting beta agonist), with a difference of 0.11 liters. It also outperformed the strategy of simply doubling the inhaled corticosteroid dose, improving FEV1 by 0.10 liters more than that approach.
These numbers may sound small in absolute terms, but for someone with poorly controlled asthma, that improvement can translate to noticeably easier breathing and fewer flare-ups.
Dosing and How to Use It
For asthma, the recommended dose is two puffs of Spiriva Respimat 1.25 mcg once daily, delivering a total daily dose of 2.5 mcg. This is notably lower than the COPD dose. Both puffs should be taken at the same time, once a day, and you should not exceed two puffs in any 24-hour period.
One critical point: Spiriva is not a rescue inhaler. It won’t help during an acute asthma attack. You still need a fast-acting bronchodilator like albuterol for sudden symptoms. Spiriva works in the background, keeping your baseline airway function better over time.
Side Effects
The most common side effect is dry mouth, which is a direct result of how the drug works (blocking the same receptors that stimulate saliva production). This is usually mild and often improves over time as your body adjusts. Other frequently reported side effects include upper respiratory tract infections, sinusitis, sore throat, and indigestion.
Less common but more serious concerns involve the eyes and urinary system. Because muscarinic receptors exist throughout the body, Spiriva can worsen narrow-angle glaucoma, causing eye pain, blurred vision, or visual halos. It can also aggravate urinary retention, particularly in men with an enlarged prostate. If you have either of these conditions, make sure your prescriber knows before starting Spiriva.
In rare cases, the inhaled medication can trigger paradoxical bronchospasm, meaning your airways tighten instead of relaxing. If this happens, stop using Spiriva and use your rescue inhaler immediately. Allergic reactions including hives, swelling of the lips or tongue, and rash are also possible but uncommon. People with a known allergy to tiotropium or ipratropium (a related medication) should not use Spiriva.
Spiriva Respimat vs. Spiriva HandiHaler
This distinction trips up many patients. Spiriva comes in two delivery devices: the Respimat (a soft-mist inhaler) and the HandiHaler (a dry powder capsule inhaler). Only the Respimat version is approved for asthma. The HandiHaler is approved solely for COPD and delivers a higher dose. If you’re being prescribed Spiriva for asthma, you should be receiving the Respimat device at the 1.25 mcg per puff strength.